Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) announced that CT Laser Mammography (CTLM(R)) clinical results will be featured at the 8th Milan Breast Cancer Conference, June 21-23, in Milan, Italy.

This year's meeting, "Innovation in Care and Research," is dedicated to breast cancer prevention, detection and treatment developments. The conference will highlight the tailoring of therapeutic approaches to the needs of the individual patient.

The Milan Breast Cancer Conference is organized by the prestigious European Institute of Oncology (EIO), a comprehensive cancer center that provides diagnostic services and treatment, conducts research, and participates in clinical trials. The EIO is also one of IDSI's clinical collaboration sites.

Italy has been an early adopter of CTLM technology in both research and clinical settings. IDSI has four installations in the country.

The CTLM results will be located at booth 7. For more information on the 8th Milan Breast Cancer Conference, visit the conference website: http://www.breastmilan.com/index.php .

As previously stated the company's CTLM system has recently entered US clinical trials for submission of the PMA application.

Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Laser Mammography (CTLM(R)) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM(R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. The CTLM system is limited by United States Federal Law to investigational use only in the United States. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system.

Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

http://www.gzjiayumed.com/en/index.asp